Trial Profile
A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs MT-2271 (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Medicago
- 13 Oct 2020 Results assessing efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus like particle influenza vaccine published in the THE LANCET
- 28 Apr 2020 Primary endpoint has not been met. (Time of occurence of protocol-defined respiratory illness due to laboratory-confirmed influenza caused by vaccine matched strains.)
- 28 Apr 2020 Results published in Mitsubishi Tanabe Pharma Corporation media release.